SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For The Quarter Ended September 30, 1996
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
--------- ------------
Commission file number 0-19386
FISCHER IMAGING CORPORATION
(Exact name of Registrant as specified in its charter)
DELAWARE 36-2756787
(State of incorporation) (I.R.S. Employer Identification No.)
12300 North Grant Street
Denver, Colorado 80241
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (303) 452-6800
Indicate by check mark whether the Registrant (i) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the Registrant was required to file such reports)
and (ii) has been subject to such filing requirements for the past 90
days. Yes X No
----- ----
Shares Outstanding as of
Title of Class September 30, 1996
--------------------- -------------------------
Common Stock, $0.01 par value 6,894,835
<PAGE>
FISCHER IMAGING CORPORATION
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION Page
----
Item 1. Consolidated Financial Statements
Consolidated Balance Sheets -
September 30, 1996 and December 31, 1995 3
Consolidated Statements of Operations -
Three and nine months ended September 30, 1996
and October 1, 1995 4
Consolidated Statements of Cash Flows -
Nine months ended September 30, 1996 and
October 1, 1995 5
Notes to Consolidated Financial Statements 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 9
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K 14
<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands except share data)
<TABLE>
<CAPTION>
September 30, December 31,
1996 1995
------------ ------------
ASSETS (Unaudited)
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $5,072 $ 968
Trade accounts receivable, net of allowance for
doubtful accounts of approximately $641 and $449
at September 30, 1996 and December 31, 1995,
respectively 22,425 19,957
Inventories 24,049 20,790
Other current assets 3,552 3,202
------ ------
Total current assets 55,098 44,917
------ ------
PROPERTY AND EQUIPMENT (at cost):
Manufacturing equipment 7,307 7,591
Office equipment and leasehold improvements 4,733 4,789
------ ------
12,040 12,380
Less-Accumulated depreciation and amortization 8,113 8,288
------ ------
Property and equipment, net 3,927 4,092
------ ------
INTANGIBLE ASSETS, net 4,493 4,798
DEFERRED COSTS AND OTHER ASSETS 1,958 1,843
------ ------
Total assets $ 65,476 $ 55,650
====== ======
LIABILITIES AND STOCKHOLDERS' INVESTMENT
CURRENT LIABILITIES:
Disbursements in transit $ 7 $ 1,088
Notes payable and current maturities of long-term debt 369 4,344
Trade accounts payable 6,609 8,352
Accrued salaries and wages 2,315 2,192
Other current liabilities 5,434 4,973
------ ------
Total current liabilities 14,734 20,949
LONG-TERM DEBT 197 378
OTHER NONCURRENT LIABILITIES 487 739
------ ------
Total liabilities 15,418 22,066
STOCKHOLDERS' INVESTMENT:
Common Stock, $.01 par value, 25,000,000 shares
authorized, 6,894,835 and 5,550,691 shares
issued and outstanding at September 30, 1996
and December 31, 1995, respectively 69 56
Series C Junior Participating Preferred Stock,
$.01 par value, 500,000 shares authorized,
no shares issued and outstanding -- --
Series D Convertible Preferred Stock, $.01 par
value, 1,333,333 shares authorized, issued and
outstanding at September 30, 1996 and December 31,
1995; liquidation preference of $10,000,000 13 13
Additional paid-in capital 48,805 34,679
Accumulated earnings (deficit) 1,233 (1,027)
Cumulative translation adjustment (62) (137)
------ ------
Total stockholders' investment 50,058 33,584
------ ------
Total liabilities and stockholders' investment $ 65,476 $ 55,650
====== ======
The accompanying notes are an integral part of these financial statements.
</TABLE>
-3-<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands except per share data)
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
------------------------------- -------------------------
September 30, October 1, September 30, October 1,
1996 1995 1996 1995
---- ---- ---- ----
<S> <C> <C> <C> <C>
NET REVENUES $ 20,886 $ 19,055 $ 62,865 $ 53,745
COST OF SALES 12,953 11,739 37,562 33,120
------ ------ ------ ------
Gross profit 7,933 7,316 25,303 20,625
OPERATING EXPENSES:
Research and development 1,816 1,625 5,025 4,977
Selling, marketing and service 4,489 3,420 13,347 10,770
General and administrative 1,265 1,266 3,538 3,490
------ ------ ------ ------
Total operating expenses 7,570 6,311 21,910 19,237
------ ------ ------ ------
EARNINGS FROM OPERATIONS 363 1,005 3,393 1,388
Interest expense (99) (107) (519) (515)
Interest income 75 19 90 42
Other income (expense), net (13) (34) 41 (104)
------ ------ ------ ------
EARNINGS BEFORE INCOME TAXES 326 883 3,005 811
Provision for income taxes 85 -- 745 --
------ ------ ------ ------
NET EARNINGS $ 241 $ 883 $ 2,260 $ 811
====== ====== ====== ======
NET EARNINGS PER COMMON
AND COMMON EQUIVALENT
SHARE $ 0.03 $ 0.13 $ 0.30 $ 0.13
====== ====== ====== ======
WEIGHTED AVERAGE COMMON
AND COMMON EQUIVALENT
SHARES OUTSTANDING 8,331 6,950 7,659 6,075
===== ===== ===== =====
The accompanying notes are an integral part of these financial statements.
</TABLE>
-4-<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited)
<TABLE>
<CAPTION>
Nine Months Ended
----------------------------------
September 30, October 1,
1996 1995
------------ ----------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings $ 2,260 $ 811
------ ------
Adjustments to reconcile net earnings to net cash
(used in ) provided by operating activities-
Depreciation and amortization 1,744 1,827
Provision for minority interests (36) 131
Other 76 151
Net changes in assets and liabilities-
Increase in trade accounts receivable (2,468) (860)
Increase in inventories (3,259) (1,506)
Increase in other current assets (350) (445)
(Increase) decrease in deferred costs and other assets (115) 153
Decrease in disbursements in transit (1,081) (34)
(Decrease) increase in trade accounts payable (1,743) 408
Increase in accrued salaries and wages 123 297
Increase (decrease) in other current liabilities 461 (2,124)
Increase (decrease) in other noncurrent liabilities 115 (95)
------- ------
Total adjustments (6,533) (2,097)
------- ------
Net cash used in operating activities (4,273) (1,286)
------ ------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (1,089) (788)
------ ------
Net cash used in investing activities (1,089) (788)
------ ------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Common Stock Offering - net 13,121
Proceeds from other sales of common stock 466 103
Proceeds from sale of preferred stock - net 9,521
Net borrowings (repayments) under line of credit agreements (2,643) (5,592)
Repayments of long-term debt (1,553) (1,556)
Decrease in cumulative translation adjustment 75 (85)
------ ------
Net cash provided by financing activities 9,466 2,391
------ ------
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS 4,104 317
CASH AND CASH EQUIVALENTS, beginning of period 968 508
------ ------
CASH AND CASH EQUIVALENTS, end of period $ 5,072 $ 825
====== ======
The accompanying notes are an integral part of these financial statements.
</TABLE>
-5-<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. GENERAL
- ----------
In the opinion of management, the accompanying unaudited consolidated
balance sheets and statements of operations and cash flows contain all
adjustments, consisting only of normal recurring items, necessary to
present fairly the financial position of Fischer Imaging Corporation
(the "Company") at September 30, 1996, its results of operations for
the three and nine months ended September 30, 1996 and October 1, 1995
and cash flows for the nine months ended September 30, 1996 and
October 1, 1995.
The unaudited consolidated financial statements presented herein have
been prepared in accordance with the instructions to Form 10-Q and do
not include all the information and note disclosures required by
generally accepted accounting principles. The financial statements
should be read in conjunction with the audited financial statements
and notes thereto contained in the Company's latest annual report on
Form 10-K for the year ended December 31, 1995.
2. INVENTORIES
- --------------
Inventories include costs of materials, direct labor and manufacturing
overhead. Inventories are priced at the lower of cost (using
primarily the last-in, first-out ("LIFO") method of valuation) or
market. Writedowns for excess or obsolete inventories are charged to
expense in the period in which conditions giving rise to the
writedowns are first recognized.
Inventories consisted of the following components (in thousands):
September 30, December 31,
1996 1995
------------- -------------
Raw materials $ 14,158 $ 12,040
Work in process and finished goods 11,093 9,952
LIFO valuation adjustment (1,202) (1,202)
------ ------
Total Inventories $ 24,049 $ 20,790
====== ======
3. OTHER CURRENT LIABILITIES
- -----------------------------
Other current liabilities consisted of the following (in thousands):
September 30, December 31,
1996 1995
------------- -------------
Customer deposits and deferred revenue $ 2,062 $ 2,132
Accrued warranty and installation costs 1,659 1,140
Other 1,713 1,701
----- -----
Total other current liabilities $ 5,434 $ 4,973
===== =====
-6-<PAGE>
4. NOTES PAYABLE AND LONG-TERM DEBT
- -----------------------------------
Notes payable and long-term debt consisted of the following (in
thousands):
September 30, December 31,
1996 1995
------------- -------------
Notes payable under bank revolving
line of credit agreement $ - $ 2,643
Promissory notes payable - 386
Non-competition note payable - 829
Capitalized lease obligations 499 791
Other 67 73
---- -----
566 4,722
Less--Current maturities (369) (4,344)
Long-term debt $ 197 $ 378
==== =====
The Company currently has a $15.0 million bank revolving line of
credit secured by accounts receivable, inventory and fixed assets.
The line of credit expires on February 1, 1997. Borrowings under the
line of credit are subject to borrowing base restrictions which, as of
September 30, 1996, did not restrict the amount available under the
line. See Note 8 to these unaudited consolidated financial statements
and "Management's Discussion & Analysis - Liquidity and Capital
Resources" for an additional discussion of the Company's line of
credit.
5. ISSUANCE OF STOCK
- --------------------
During the second quarter of 1995, the Company issued 1,333,333 shares
of Series D Convertible Preferred Stock for $10.0 million. The
preferred stock is non-voting and not redeemable, bears no stated
dividend, has a $7.50 per share preference upon liquidation and is
convertible into common stock on a one-for-one basis (subject to
customary anti-dilution protection) at the option of the holder.
On June 27, 1996, the Company completed the sale of 1,200,000 shares
of its common stock at $12.00 per share. Proceeds, net of
underwriting discount and other expenses, of $13,121,000 were received
in early July 1996 and were primarily utilized to repay existing
indebtedness under the Company's bank revolving line of credit of
approximately $6.4 million. The remaining proceeds were invested in
short-term, investment grade securities.
6. NET EARNINGS (LOSS) PER COMMON AND COMMON EQUIVALENT SHARE
- -------------------------------------------------------------
Net earnings (loss) per share is computed based on results of
operations attributable to common stock and the weighted average
number of common and common equivalent shares outstanding during each
of the periods. The 1,333,333 shares of Series D Convertible
Preferred Stock issued during the second quarter of 1995 (see Note 5)
are treated as common stock equivalents in the calculation of earnings
per share. The Company uses the treasury stock method for determining
the effect of outstanding stock options on earnings per share.
-7-<PAGE>
Earnings per share are calculated by dividing the net earnings by the
weighted average of common and common equivalent shares outstanding
during each of the periods.
7. FISCHER MIDWEST MINORITY INTEREST
- ------------------------------------
During the fourth quarter of 1995, the Company reached an agreement in
principle for the acquisition of the 45% minority interest of Fischer
Imaging Midwest, Inc. in exchange for 63,162 shares of the Company's
stock. The Company accounted for this transaction, which closed in
February 1996, as a purchase, acquiring net assets with a net book
value of approximately $331,000 and recording goodwill of
approximately $221,000 which is to be amortized on a straight-line
basis over 40 years. As part of the acquisition agreement, the
purchase price may be adjusted based on subsequent realization of
certain working capital assets. The Company placed 10,000 of the
shares of Company stock in escrow, pending the outcome of this
potential purchase price adjustment, which is expected to be completed
during the last half of 1996.
-8-<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion of results of operations and financial
condition contains, in addition to historical information,
forward-looking statements which involve risks and uncertainties.
The Company's actual results may differ significantly from the results
discussed in such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not limited
to, those discussed below and in the Company's 1995 Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and "Risk Factors" section
of the Company's Registration Statement on Form S-2 that was declared
effective on June 27, 1996.
Overview
The Company designs, manufactures and markets specialty and general
purpose medical imaging systems for the diagnosis and treatment of
disease. The Company's newest product lines are directed towards
medical specialties in which image-guided, minimally-invasive
therapies are replacing open surgical procedures. These products are
used primarily in the diagnosis and treatment of breast cancer, heart
disease and vascular disease. The Company also designs and
manufactures specialty x-ray imaging components and subsystems for
several leading medical products companies as an original equipment
manufacturer ("OEM") and sells general radiology systems for use in
hospitals, clinics and physicians' offices.
The Company's future profitability will depend on many factors,
including demand for the Company's products and the ability of the
Company to maintain or increase gross margins, control manufacturing
and other costs, implement its marketing and sales strategies in the
United States and internationally, maintain orders under OEM
agreements, renew OEM agreements on favorable terms and develop and
introduce new products that compete successfully.
The Company has experienced and is likely to continue to experience
significant quarterly and annual fluctuations in net revenues,
operating results and net income, depending on such factors as the
timing of large system shipments to customers, the timing of orders
under OEM contracts and related manufacturing and shipment scheduling,
new product introductions and new marketing programs by the Company
and its competitors, delays in contract development projects, the
effect of economic conditions on the Company's markets, the effects of
managed healthcare on capital expenditures and reimbursement,
increases in marketing and research costs in relation to sales,
regulatory clearance of new products, seasonal purchasing patterns of
hospitals and the timing of purchasing decisions by customers.
Additionally, because the timing of the occurrence of such factors is
difficult to anticipate and many of the Company's costs are fixed, the
Company may not be able to sufficiently reduce its costs in periods
when its revenues are less than anticipated and may suffer unexpected
losses or lower income in these periods. For example, during the
three months ended September 30, 1996, the Company's order rate for
its Mammotest breast biopsy systems were flat when compared to 1995,
versus anticipated increases, due to increased competition from a
major surgical supply company, and lower than expected orders
-9-<PAGE>
from an OEM customer which caused lower absorption of its fixed
manufacturing costs. See "--Results of Operations."
The Company is expanding its international sales and marketing
efforts, which can be expected to result in losses from its
international operations until its international revenues reach
sufficient levels. Additionally, the Company's exposure to the risks
of international business, including foreign currency risks, may
increase as its international business grows. The Company attempts to
minimize these risks through measures including, but not limited to,
requiring payments in U.S. dollars and the use of dollar-denominated
letters of credit. There can be no assurance, however, that the
Company will be successful in its international sales efforts or in
minimizing any associated risks.
Results of Operations
The Company's net revenues and net income were $20,886,000 and
$241,000, respectively, for the third quarter of 1996. Compared to
the second quarter of 1996, the Company's sales of its
electrophysiology and general radiography products increased, but
sales of its Mammotest breast biopsy systems and sales of its Tilt-C
systems to GE Medical Systems decreased. The Company's earnings for
the third quarter were negatively affected by these decreased sales
and by lower absorption of its fixed manufacturing costs, which
declined particularly as a result of lower levels of third quarter
production activity in anticipation of a decrease in fourth quarter
1996 shipments of Tilt-C systems. The Company believes that the
disappointing Mammotest system sales resulted primarily from the
aggressive marketing efforts in the surgical breast biopsy market by a
major surgical supply company that is marketing a large diameter core
needle biopsy device with a competitor's breast biopsy table. The
Company expects this increased competition to continue to affect sales
of the Mammotest system.
The following table sets forth the percentage of net revenues
represented by certain data included in the Company's statements of
operations for the periods indicated:
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
-------------------------------- -------------------------
September 30, October 1, September 30, October 1,
1996 1995 1996 1995
---- ---- ---- ----
<S> <C> <C> <C> <C>
Net revenues 100.0% 100.0% 100.0% 100.0%
Gross profit 38.0 38.4 40.2 38.4
Research and development 8.7 8.5 8.0 9.3
Selling, marketing and service 21.5 17.9 21.2 20.0
General and administrative 6.1 6.6 5.6 6.5
Earnings from operations 1.7 5.3 5.4 2.6
Provision for income taxes 0.4 0.0 1.2 0.0
Net earnings (loss) 1.2 4.6 3.6 1.5
</TABLE>
Net Revenues. Third quarter net revenues were $20,886,000, an
increase of 9.6% from third quarter 1995 net revenues of $19,055,000.
Net revenues for the nine months ended September 30, 1996 were
$62,865,000, a 17.0% increase over net revenues of $53,745,000 for the
comparable nine month period of 1995. The Company's relative
-10-<PAGE>
increase in revenues for the three months ended September 30, 1996
compared to the same period in 1995 reflects strong increases in sales
of electrophysiology and general radiography products and, for the
comparable nine month periods, principally reflects expanded OEM
shipments (primarily the Tilt-C system sold to GE Medical Systems but
also sales of lithotripter products to Dornier and Storz), as well as
increased sales of general radiography products, sold principally
through the domestic dealer channel, and increased service revenue.
For the three months ended September 30, 1996, international revenues
were modestly higher than the comparable three months of 1995,
although international revenues for the nine months ended September
30, 1996 declined slightly from the comparable nine months of 1995.
The decline for the nine month period was due primarily to the effect
of a large system sale that occurred during the comparable nine month
period of 1995. The Company anticipates a change in its sales mix over
the remainder of 1996, as increases in some OEM products and products
sold through the Company's direct and dealer channels are offset by
decreases in sales of Tilt-C systems. The Company also anticipates
that its Mammotest systems will continue to face strong competition in
the surgical market.
Gross Profit. For the third quarter of 1996, gross profit expressed
as a percentage of net revenues was 38.0%, approximately the same as
the 38.4% for the third quarter of 1995, as the unfavorable effects of
a decline in margin on OEM sales was largely offset by a shift in
product mix to higher margin electrophysiology products. For the nine
months ended September 30, 1996, gross profit as a percentage of net
revenues was 40.2%, up from 38.4% for the nine months ended October 1,
1995. This improvement was due to manufacturing cost reductions and
the higher manufacturing cost absorption associated with higher
volumes, partially offset by the effects of the shift in product mix
to lower margin OEM sales.
Research and Development Expenses. Research and development expenses
for the third quarter of 1996 and 1995 were $1,816,000 and $1,625,000,
respectively. As a percentage of net revenues, third quarter 1996 and
1995 research and development expenses were 8.7% and 8.5%,
respectively. The higher level of research and development expenses
over last year relates primarily to the continuing development of
digital imaging products for mammography. This trend can be expected
to continue. For the nine months ended September 30, 1996 and October
1, 1995, research and development expenses were $5,025,000, or 8.0% of
net revenues, and $4,977,000, or 9.3% of net revenues, respectively.
The increase in research and development expenses for the nine months
ended September 30, 1996 as compared to the nine months ended October
1, 1995 is primarily attributable to the continuing development of
digital imaging products for mammography, whereas the decline as a
percentage of revenues is due to engineering efforts temporarily
assigned to product enhancement and other production activities during
the first quarter of 1996.
Selling, Marketing and Service Expenses. Selling, marketing and
service expenses for the third quarter of 1996 and 1995 were
$4,489,000 and $3,420,000, respectively, or 21.5% and 17.9%,
respectively, of net revenues. The increase as a percentage of net
revenues reflects increases in sales through the direct sales channel,
for which the Company incurs commissions, warranty and installation
expenses, as compared to the comparable three months of 1995. For the
nine months ended September 30, 1996, selling, marketing and
-11-<PAGE>
services expenses were $13,347,000, or 21.2% of net revenues, as
compared to $10,770,000, or 20.0% of net revenues, for the comparable
nine month period of 1995. As a percentage of net revenues, selling,
marketing and service expenses for the nine months ended September 30,
1996 were unfavorably impacted by increased commissions, warranty and
installation expenses associated with higher sales through the direct
sales channel and by higher service expenses as compared to the
comparable nine months of 1995. Service expenses were higher in 1996
due to expanded international service activity, as well as a lower
level of completed installation activity in 1996, for which the
service department receives credit at time of installation; whereas,
the related expense provisions for installation credits are provided
at time of sale.
General and Administrative Expenses. General and administrative
expenses for the third quarter of 1996 and 1995 were essentially
unchanged at $1,265,000 and $1,266,000, respectively. As a
percentage of net revenues, general and administrative expenses
declined from 6.6% to 6.1% from the third quarter of 1995 to the third
quarter of 1996. For the nine months ended September 30, 1996,
general and administrative expenses were $3,538,000, or 5.6% of net
revenues, as compared to $3,490,000, or 6.5% of net revenues for the
comparable period of 1995. For both the three and nine month periods
ended September 30, 1996, the reduction in general and administrative
expenses as a percentage of net revenues is primarily due to the
change in net revenues, which increased more rapidly than
administrative expenses.
Interest Expense. Interest expense for the third quarter of 1996 and
1995 was $99,000 and $107,000, respectively. For the nine months ended
September 30, 1996, interest expense was $519,000, as compared to
$515,000 for the first nine months of 1995. The change in interest
expense is principally related to changes in outstanding borrowings
under the Company's revolving line of credit and other borrowing
arrangements. The amount of the Company's borrowings under its line
of credit have been primarily a function of working capital
requirements, which have increased as a result of higher revenues and
production requirements, as well as the amount of proceeds from sales
of Company stock. (See Note 5.)
Net Earnings (Loss). The Company's net earnings for the third
quarter of 1996 was $241,000 as compared to $883,000 for the third
quarter of 1995. For the nine months ended September 30, 1996, net
earnings was $2,260,000 as compared to a net earnings of $811,000 for
the comparable nine month period of 1995. For the three month period
ended September 30, 1996 net earnings were unfavorably impacted by the
higher sales, marketing and service expenses associated with a change
in mix to sales through the direct sales channel, as compared to the
comparable three month period of 1995, partially offset by the
favorable effects of higher sales of electrophysiology products at
higher margins. For the nine period ended September 30, 1996, net
earnings benefited from increased OEM shipments and reductions in and
improved absorption of manufacturing expenses as compared to the
comparable period in 1995. For both the three and nine month periods
ended September 30, 1996, net earnings decreased from the comparable
three and nine month periods of 1995 because income taxes were
required to be provided at an estimated annual effective rate of 25%;
whereas, in 1995, due to the Company's cumulative net losses, no
income tax provision was required.
-12-<PAGE>
Income Taxes
Based upon anticipated earnings for the year, an anticipated reduction
in the valuation allowance on deferred tax assets, and a review of
other factors giving rise to differences between statutory and
effective income tax rates, the Company has estimated its effective
tax rate for the year ended December 31, 1996 to be approximately
25.0% and, accordingly, has provided income taxes in the three and
nine month periods ended September 30, 1996 of $85,000 and $745,000,
respectively, against earnings before taxes of $326,000 and
$3,005,000, respectively. Because of an anticipated reduction in the
valuation allowance on deferred tax assets and a review of other
factors giving rise to differences between statutory and effective
income tax rates, the Company provided no income taxes for the three
and nine month periods ended October 1, 1995.
Liquidity and Capital Resources
Net cash used in operating activities for the nine months ended
September 30, 1996 was $4.3 million compared to $1.3 million in the
same period in 1995. The increase in cash flows used in operations
principally reflects higher investment in inventories and accounts
receivable and a reduction in trade accounts payable in 1996,
partially offset by a $1.5 million improvement in net earnings.
Net cash used in investing activities was $1.1 million for the nine
months ended September 30, 1996, compared to $0.8 million for the same
period in 1995.
Net cash provided by financing activities for the nine months ended
September 30, 1996 was $9.5 million, compared to $2.4 million for the
same period in 1995. During the third quarter ended September 30,
1996 the Company received approximately $13.1 million in proceeds, net
of underwriters' discount and other expenses, from the sale of 1.2
million shares of its common stock. These proceeds were primarily
utilized to repay existing indebtedness under the Company's bank
revolving line of credit of approximately $6.4 million. The remaining
proceeds were invested in short-term, investment grade securities.
As of September 30, 1996, the Company had $5.1 million in cash and
cash equivalents and working capital of $40.4 million. Currently, the
Company has in place a $15.0 million working capital line of credit,
which is secured by accounts receivable, inventory and fixed assets.
The borrowings under the line of credit are subject to borrowing base
restrictions. As of September 30, 1996, there were no borrowings
against the line and borrowing base restrictions did not limit
borrowing availability. The Company believes its current level of
operations, available borrowing capacity and the proceeds from its
recently completed equity financing will be sufficient to fund
foreseeable working capital and capital expenditure needs.
-13-
<PAGE>
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K:
- ----------------------------------------
(a) Exhibits
- -------------
Exhibits filed with this report:
Exhibit No. Description
----------- -----------
27 Financial Data Schedule
(b) Reports on Form 8-K
- ------------------------
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Quarterly Report on Form 10-Q for
the quarter ended September 30, 1996 to be signed on its behalf by the
undersigned thereunto duly authorized.
FISCHER IMAGING CORPORATION
/S/ James A. Newcomb
---------------------
James A. Newcomb
Vice President Finance /
Chief Financial Officer
November 14, 1996
-14-<PAGE>
Exhibit Index
-------------
Exhibit No. Description
- ----------- -----------
27 Financial Data Schedule
-15-
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-END> SEP-30-1996
<CASH> 5,072
<SECURITIES> 0
<RECEIVABLES> 23,066
<ALLOWANCES> 641
<INVENTORY> 24,049
<CURRENT-ASSETS> 55,098
<PP&E> 12,040
<DEPRECIATION> 8,113
<TOTAL-ASSETS> 65,476
<CURRENT-LIABILITIES> 14,734
<BONDS> 197
0
13
<COMMON> 69
<OTHER-SE> 49,976
<TOTAL-LIABILITY-AND-EQUITY> 65,476
<SALES> 20,886
<TOTAL-REVENUES> 20,886
<CGS> 12,953
<TOTAL-COSTS> 12,953
<OTHER-EXPENSES> 7,570
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 99
<INCOME-PRETAX> 326
<INCOME-TAX> 85
<INCOME-CONTINUING> 241
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 241
<EPS-PRIMARY> .03
<EPS-DILUTED> .03
</TABLE>
